<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5061703 - Alzheimer*s disease - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Alzheimer*s disease"><meta name="DC.contributor" content="Joachim Bormann" scheme="inventor"><meta name="DC.contributor" content="Markus R. Gold" scheme="inventor"><meta name="DC.contributor" content="Wolfgang Schatton" scheme="inventor"><meta name="DC.contributor" content="Merz + Co. Gmbh &amp; Co." scheme="assignee"><meta name="DC.date" content="1990-4-11" scheme="dateSubmitted"><meta name="DC.description" content="A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R3 and R4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R5 is hydrogen or a straight or branched C1 -C6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed."><meta name="DC.date" content="1991-10-29" scheme="issued"><meta name="DC.relation" content="EP:0227410:A2" scheme="references"><meta name="citation_reference" content="Berkow, R.; The Merck Manual. 15, pp. 1336 1340 (1987)."><meta name="citation_reference" content="Berkow, R.; The Merck Manual. 15, pp. 1336-1340 (1987)."><meta name="citation_reference" content="Hamoen, A. M.; British Medical Journal. 3, (5874), pp. 272 273 (1973)."><meta name="citation_reference" content="Hamoen, A. M.; British Medical Journal. 3, (5874), pp. 272-273 (1973)."><meta name="citation_reference" content="Hossman, K. A.; Critical Care Medicine. 16 (10), pp. 964 971 (1988)."><meta name="citation_reference" content="Hossman, K. A.; Critical Care Medicine. 16 (10), pp. 964-971 (1988)."><meta name="citation_reference" content="Hoyer, S.; Aging. 11, pp. 158 166 (1988)."><meta name="citation_reference" content="Hoyer, S.; Aging. 11, pp. 158-166 (1988)."><meta name="citation_reference" content="Kinomota, H. et al.; No Skinkei Geka, 12 (1), pp. 37 45 (1984)."><meta name="citation_reference" content="Kinomota, H. et al.; No Skinkei Geka, 12 (1), pp. 37-45 (1984)."><meta name="citation_reference" content="Krieglstein, J., Weber, J. in Oxygen Transport to Tissue, VIII, Longmuir, I. S., Editor; Plenum Publishing Corporation; pp. 243 253 (1986)."><meta name="citation_reference" content="Krieglstein, J., Weber, J. in Oxygen Transport to Tissue, VIII, Longmuir, I. S., Editor; Plenum Publishing Corporation; pp. 243-253 (1986)."><meta name="citation_reference" content="Marcy, R. et al.; J. Pharmacol. 13 (1), pp. 163 164 (1982)."><meta name="citation_reference" content="Marcy, R. et al.; J. Pharmacol. 13 (1), pp. 163-164 (1982)."><meta name="citation_reference" content="Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1268 1270 (1982)."><meta name="citation_reference" content="Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1268-1270 (1982)."><meta name="citation_reference" content="Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1271 1273 (1982)."><meta name="citation_reference" content="Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1271-1273 (1982)."><meta name="citation_reference" content="Miura, Y. et al.; Japan. J. Pharmacol. 39, pp. 443 451 (1986)."><meta name="citation_reference" content="Miura, Y. et al.; Japan. J. Pharmacol. 39, pp. 443-451 (1986)."><meta name="citation_reference" content="Otomo, E; Japan. J. Neuropsychopharmacol. 4/2, pp. 113 119 (1982)."><meta name="citation_reference" content="Otomo, E; Japan. J. Neuropsychopharmacol. 4/2, pp. 113-119 (1982)."><meta name="citation_reference" content="Sugio, K. et al.; Japan. J. Pharmacol. 47, pp. 327 329 (1988)."><meta name="citation_reference" content="Sugio, K. et al.; Japan. J. Pharmacol. 47, pp. 327-329 (1988)."><meta name="citation_patent_number" content="US:5061703"><meta name="citation_patent_application_number" content="US:07/508,109"><link rel="canonical" href="http://www.google.com/patents/US5061703"/><meta property="og:url" content="http://www.google.com/patents/US5061703"/><meta name="title" content="Patent US5061703 - Alzheimer*s disease"/><meta name="description" content="A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R3 and R4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R5 is hydrogen or a straight or branched C1 -C6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed."/><meta property="og:title" content="Patent US5061703 - Alzheimer*s disease"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("LSnuU-ehF6SlsQSy4YF4"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("PRT"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("LSnuU-ehF6SlsQSy4YF4"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("PRT"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5061703?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5061703"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=7VwxBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5061703&amp;usg=AFQjCNEEJQja5riirXD_pMfUtCEJ6Fi6MA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5061703.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5061703.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5061703" style="display:none"><span itemprop="description">A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R1 and R2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6...</span><span itemprop="url">http://www.google.com/patents/US5061703?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5061703 - Alzheimer*s disease</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5061703 - Alzheimer*s disease" title="Patent US5061703 - Alzheimer*s disease"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5061703 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 07/508,109</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Oct 29, 1991</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 11, 1990</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 14, 1989</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2014453A1">CA2014453A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2014453C">CA2014453C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE10299048I1">DE10299048I1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE10299048I2">DE10299048I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE58905637D1">DE58905637D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0392059A1">EP0392059A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0392059B1">EP0392059B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">07508109, </span><span class="patent-bibdata-value">508109, </span><span class="patent-bibdata-value">US 5061703 A, </span><span class="patent-bibdata-value">US 5061703A, </span><span class="patent-bibdata-value">US-A-5061703, </span><span class="patent-bibdata-value">US5061703 A, </span><span class="patent-bibdata-value">US5061703A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Joachim+Bormann%22">Joachim Bormann</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Markus+R.+Gold%22">Markus R. Gold</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Wolfgang+Schatton%22">Wolfgang Schatton</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Merz+%2B+Co.+Gmbh+%26+Co.%22">Merz + Co. Gmbh & Co.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5061703.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5061703.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5061703.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (1),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (24),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (85),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (15),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (10)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5061703&usg=AFQjCNG1fkuqX0KxFx4FeoVyCfV2xhPIbg">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5061703&usg=AFQjCNEXm7XABD2nEJKwzoX6EVmpx7GKNw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5061703A%26KC%3DA%26FT%3DD&usg=AFQjCNEwnxrDS1nEzmKj8lzBONIkekecJw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129483706" lang="EN" load-source="ifi">Alzheimer*s disease</invention-title></span><br><span class="patent-number">US 5061703 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA131124441" lang="EN" load-source="patent-office"> <div class="abstract">A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R<sub>1</sub> and R<sub>2</sub> are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;</div>
    <div class="abstract">wherein</div>
    <div class="abstract">R<sub>3</sub> and R<sub>4</sub> are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;</div>
    <div class="abstract">wherein</div>
    <div class="abstract">R<sub>5</sub> is hydrogen or a straight or branched C<sub>1</sub> -C<sub>6</sub> alkyl group,</div>
    <div class="abstract">or a pharmaceutically-acceptable salt thereof, is disclosed.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(12)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5061703-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5061703-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(13)</span></span></div><div class="patent-text"><div mxw-id="PCLM59063171" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for the prevention or treatment of cerebral ischemia comprising the step of administering, to a patient in need thereof, an effective amount of an adamantane derivative of the general formula ##STR5## wherein R<sub>1</sub> and R<sub>2</sub> are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;<div class="claim-text">wherein</div> <div class="claim-text">R<sub>3</sub> and R<sub>4</sub> are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;<div class="claim-text">wherein</div> </div> <div class="claim-text">R<sub>5</sub> is hydrogen or a straight or branched C<sub>1</sub> -C<sub>6</sub> alkyl group,<div class="claim-text">or a pharmaceutically-acceptable salt thereof.</div> </div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A method according to claim 1, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are hydrogen.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A method according to claim 2, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are hydrogen, and R<sub>3</sub> and R<sub>4</sub> are methyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A method according to claim 2, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are hydrogen, and R<sub>3</sub> and R<sub>4</sub> are ethyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A method according to claim 1, wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen, and R<sub>3</sub> is ethyl, isopropyl, or cyclohexyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A method according to claim 1, wherein R<sub>2</sub> and R<sub>5</sub> are hydrogen.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A method according to claim 6, wherein R<sub>3</sub> and R<sub>4</sub> are methyl, R<sub>2</sub> and R<sub>5</sub> are hydrogen and R<sub>1</sub> is methyl or ethyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. A method according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A method according to claim 8, wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen, R<sub>3</sub> is ethyl, and R<sub>5</sub> and R<sub>4</sub> are methyl.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. A method according to claim 1 for the treatment of Alzheimer's disease.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. A method of claim 1, wherein the adamantane derivative is administered in an effective cerebral ischemia-alleviating or preventive amount.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. A method of claim 11, wherein the adamantane derivative is administered in the form of a composition containing the same together with a pharmaceutically-acceptable carrier or diluent.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. A method of claim 11, wherein the adamantane derivative is administered in an amount effective to prevent degeneration and loss of nerve cells after ischemia.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66128277" lang="EN" load-source="patent-office" class="description">
    <p>The present invention relates to a method for the prevention or treatment of cerebral ischemia using an adamantane derivative of the following general formula ##STR2## wherein R<sub>1</sub> and R<sub>2</sub> are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic radical with 5 or 6 ring C atoms;</p>
    <p>wherein</p>
    <p>R<sub>3</sub> and R<sub>4</sub> are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; and</p>
    <p>wherein</p>
    <p>R<sub>5</sub> is hydrogen or a straight or branched C<sub>1</sub> -C<sub>6</sub> alkyl group, or a pharmaceutically-acceptable acid addition salt thereof. Herein branched or straight C<sub>1</sub> -C<sub>6</sub> alkyl groups representatively include methyl, ethyl, iso- and n-propyl, n-, iso- and t-butyl, n-pentyl, n-hexyl, and the isomers thereof.</p>
    <p>Certain 1-amino adamantanes of formula (I) are known. 1-amino-3,5-dimethyl adamantane, for example, is the subject matter of German patents 22 19 256 and 28 56 393.</p>
    <p>Some 3,5-disubstituted 1-amino adamantanes of formula (I) are described in U.S. Pat. No. 4,122,193. 1-amino-3-ethyl adamantane is described in German Patent 22 32 735.</p>
    <p>The compounds of formula (I) are generally prepared by alkylation of halogenated adamantanes, preferably bromo- or chloroadamantanes. The di- or tri-substituted adamantanes are obtained by additional halogenation and alkylation procedures. The amino group is introduced either by oxidation with chromiumtrioxide and bromination with HBr or bromination with bromine and reaction with formamide followed by hydrolysis. The amino function can be alkylated according to generally-accepted methods. Methylation can, for example, be effected by reaction with chloromethyl formate and subsequent reduction. The ethyl group can be introduced by reduction of the respective acetamide.</p>
    <p>In accordance with U.S. Pat. No. 4,122,193 amination can also be effected by reaction of the respective 1-halogen-3,5- or -7-substituted adamantane with a urea derivative of the formula ##STR3## wherein R<sub>1</sub> is hydrogen or alkyl.</p>
    <p>The compounds according to formula (I) are prepared according to the following reaction scheme: ##STR4##</p>
    <p>Alkylation of the halogenated adamantanes can be achieved by known methods, for example, through Friedel-Crafts reaction (introduction of phenyl group), or by reaction with vinylidene chloride, subsequent reduction and suitable Wittig reaction of the aldehydes and subsequent hydration, or by introduction of ethylene and subsequent alkylation with appropriate cuprates, or by introduction of ethylene and reduction of the halogen alkyl adamantanes, or by acylation with CO<sub>2</sub> and reduction of the carboxylic acid.</p>
    <p>The compounds according to formula (I) known from the above-cited patents have so far been used for the treatment of parkinsonian and parkinsonoid diseases. Their mode of action is attributed to a dopaminergic influence on the CNS, either by an increased release of the transmitter substance dopamine or by an inhibition of its uptake. This compensates the imbalance of the dopamine/acetylcholine system.</p>
    <p>In contrast to this type of disease, cerebral ischemia is characterized by a pathophysiological situation defined by an imbalance of neuronal stimulation mechanisms. In this context, the excessive inflow of calcium through NMDA receptor channels finally leads to the destruction of brain cells in specific brain areas (Rothmann &amp; Olney, Trends Neurosci 10, 1989, pp. 299).</p>
    <p>Therefore, in order to treat or eliminate this pathological situation, an antagonistic intervention is required with regard to the NMDA receptor channels (Kemp et al., Trends Pharmacol., Sci. 8, 1987. pp. 414).</p>
    <p>Such intervention can, for example, be effected using substituted fluoro and hydroxy derivatives of dibenzo-[a,d]-cyclo-heptene-5,10-imine which are described in EP-A 0 264 183.</p>
    <p>These heterocyclic, aromatic compounds are lipophilic and exhibit NMDA receptor channel-antagonistic and anticonvulsive properties. They are prepared by a relatively expensive method generating enantiomer mixtures which may be split into the individual optical antipodes.</p>
    <p>The present invention is aimed at preparing and employing compounds which can be chemically generated by simple methods, exhibiting an NMDA receptor channel-antagonistic and anticonvulsive action, for use in the prevention and treatment of cerebral ischemia.</p>
    <p>This objective can be achieved according to the invention by using the 1-amino adamantanes of formula (I).</p>
    <p>It has been found unexpectedly that the use of these compounds prevents an impairment or further impairment, i.e., degeneration and loss of nerve cells, after ischemia. Therefore, the adamantane derivatives of formula (I) are especially suited for the prevention and treatment of cerebral ischemia after apoplexy, open-heart surgery, cardiac standstill, subarachnoidal homorrhage, transient cerebro-ischemic attacks, perinatal asphyxia, anoxia, hypoglycemia, apnoea and Alzheimer's disease. The amount employed is a cerebral ischemia-alleviating or preventive amount.</p>
    <p>Examples of compounds prepared and used according to the invention are:</p>
    <p>1-amino adamantane</p>
    <p>1-amino-3-phenyl adamantane</p>
    <p>1-amino-methyl-adamantane</p>
    <p>1-amino-3,5-dimethyl adamantane (test compound no. 1)</p>
    <p>1-amino-3-ethyl adamantane (test compound no. 2)</p>
    <p>1-amino-3-isopropyl adamantane (test compound no. 3)</p>
    <p>1-amino-3-n-butyl adamantane</p>
    <p>1-amino-3,5-diethyl adamantane (test compound no. 4)</p>
    <p>1-amino-3,5-diisopropyl adamantane</p>
    <p>1-amino-3,5-di-n-butyl adamantane</p>
    <p>1-amino-3-methyl-5-ethyl adamantane</p>
    <p>1-N-methylamino-3,5-dimethyl adamantane (test compound no. 5)</p>
    <p>1-N-ethylamino-3,5-dimethyl adamantane (test compound no. 6)</p>
    <p>1-N-isopropyl-amino-3,5-dimethyl adamantane</p>
    <p>1-N,N-dimethyl-amino-3,5-dimethyl adamantane</p>
    <p>1-N-methyl-N-isopropyl-amino-3-methyl-5-ethyl adamantane</p>
    <p>1-amino-3-butyl-5-phenyl adamantane</p>
    <p>1-amino-3-pentyl adamantane</p>
    <p>1-amino-3,5-dipentyl adamantane</p>
    <p>1-amino-3-pentyl-5-hexyl adamantane</p>
    <p>1-amino-3-pentyl-5-cyclohexyl adamantane</p>
    <p>1-amino-3-pentyl-5-phenyl adamantane</p>
    <p>1-amino-3-hexyl adamantane</p>
    <p>1-amino-3,5-dihexyl adamantane</p>
    <p>1-amino-3-hexyl-5-cyclohexyl adamantane</p>
    <p>1-amino-3-hexyl-5-phenyl adamantane</p>
    <p>1-amino-3-cyclohexyl adamantane (test compound no. 7)</p>
    <p>1-amino-3,5-dicyclohexyl adamantane</p>
    <p>1-amino-3-cyclohexyl-5-phenyl adamantane</p>
    <p>1-amino-3,5-diphenyl adamantane</p>
    <p>1-amino-3,5,7-trimethyl adamantane</p>
    <p>1-amino-3,5-dimethyl-7-ethyl adamantane (test compound no. 8)</p>
    <p>1-amino-3,5-diethyl-7-methyl adamantane</p>
    <p>1-N-pyrrolidino and 1-N-piperidine derivatives,</p>
    <p>1-amino-3-methyl-5-propyl adamantane</p>
    <p>1-amino-3-methyl-5-butyl adamantane</p>
    <p>1-amino-3-methyl-5-pentyl adamantane</p>
    <p>1-amino-3-methyl-5-hexyl adamantane</p>
    <p>1-amino-3-methyl-5-cyclohexyl adamantane</p>
    <p>1-amino-3-methyl-5-phenyl adamantane</p>
    <p>1-amino-3-ethyl-5-propyl adamantane</p>
    <p>1-amino-3-ethyl-5-butyl adamantane</p>
    <p>1-amino-3-ethyl-5-pentyl adamantane</p>
    <p>1-amino-3-ethyl-5-hexyl adamantane</p>
    <p>1-amino-3-ethyl-5-cyclohexyl adamantane</p>
    <p>1-amino-3-ethyl-5-phenyl adamantane</p>
    <p>1-amino-3-propyl-5-butyl adamantane</p>
    <p>1-amino-3-propyl-5-pentyl adamantane</p>
    <p>1-amino-3-propyl-5-hexyl adamantane</p>
    <p>1-amino-3-propyl-5-cyclohexyl adamantane</p>
    <p>1-amino-3-propyl-5-phenyl adamantane</p>
    <p>1-amino-3-butyl-5-pentyl adamantane</p>
    <p>1-amino-3-butyl-5-hexyl adamantane</p>
    <p>1-amino-3-butyl-5-cyclohexyl adamantane</p>
    <p>their N-methyl, N,N-dimethyl, N-ethyl, N-propyl derivatives and their acid addition compounds.</p>
    <p>Preferred compounds of formula (I) are those wherein R<sub>1</sub> and R<sub>2</sub> are hydrogen such as, for example, 1-amino-3-ethyl-5,7-dimethyl adamantane, and compounds wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen such as, for example, 1-amino-3-cyclohexyl adamantane and 1-amino-3-ethyl adamantane.</p>
    <p>Additional preferred compounds are those wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are hydrogen such as, for example, 1-amino-3-methyl-5-propyl or 5-butyl adamantane, 1-amino-3-methyl-5-hexyl or cyclohexyl adamantane, or 1-amino-3-methyl-5-phenyl adamantane.</p>
    <p>Especially preferred compounds are 1-amino-3,5-dimethyl adamantane, 1-amino-3,5-diethyl adamantane, i.e., compounds wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>5</sub> are hydrogen, and compounds wherein R<sub>1</sub> and R<sub>5</sub> are hydrogen, R<sub>2</sub> is methyl or ethyl, and R<sub>3</sub> and R<sub>4</sub> are methyl such as, for example, 1-N-methylamino-3,5-dimethyl adamantane and 1-N-ethylamino-3,5-dimethyl adamantane.</p>
    <p>The adamantane derivatives of formula (I) may be applied as such or in the form of their pharmaceutically-acceptable acid addition salts including, for example, the hydrochlorides, hydrobromides, sulfates, acetates, succinates or tartrates, or their acid addition salts with fumaric, maleic, citric, or phosphoric acids.</p>
    <p>The compounds of formula (I) are administered in suitable form in doses ranging from about 0.01 to 100 mg/kg. Appropriate presentation forms are, for example, combinations of the active substance with common pharmaceutical carriers and adjuvants in the form of tablets, coated tablets, and sterile solutions or suspensions for injection. Pharmaceutically-acceptable carriers are, for example, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, gum arabic, corn starch, or cellulose, combined with diluents such as water, polyethylene glycol, etc. Solid presentation forms are prepared according to common methods and may contain up to 50 mg of the active ingredient per unit.</p>
    <p>The efficacy of the compounds of formula (I) is described in the following pharmacological tests.</p>
    <heading>A. Displacement of TCP Binding</heading> <p>Phencyclidine (PCP), a known NMDA antagonist, binds to the NMDA receptor-associated ionic channel and blocks ionic transport (Garthwaite &amp; Garthwaite, Neurosci. Lett. 83, 1987, 241-246). Additionally, PCP has been shown to prevent the destruction of brain cells after cerebral ischemia in rats (Sauer et al., Neurosci. Lett. 91, 1988, 327-332).</p>
    <p>The interaction between compounds of formula (I) and the PCP bond is studied in the following. In this test <sup>3</sup> H-TCP, a PCP analogue, is used.</p>
    <p>A membrane preparation of rat cortex is incubated with <sup>3</sup> H-TCP which is an analogue of phencyclidine (PCP) (Quirion &amp; Pert 1982, Eur. J. Pharmacol. 83:155). The interaction with the TCP binding is assessed for test compound no. 1 (1-amino-3,5-dimethyl adamantane) in a competitive experiment. This test shows that compound no. 1 is very effective in displacing TCP from the bond. The IC<sub>50</sub> value is 89 nM. The conclusion can be drawn that compound no. 1 binds to NMDA receptor channels at the same site as the NMDA antagonist PCP.</p>
    <heading>B. Blocking of NMDA Receptor Channels</heading> <p>In the following test it is shown that the compounds of formula (I) according to the invention are as effective as PCP in blocking the NMDA receptor channel.</p>
    <p>In the patch-clamp experiment, the current flowing through NMDA-activated membrane channels of cultivated spinal marrow neurons (mouse) is measured (Hamill et al 1981, Pflugers Arch. 312: 85-100). After application of 20 μM NMDA, the current signal of the cell is integrated for 20 sec. and recorded as a control answer (A<sub>c</sub>). During succeeding application of 20 μM NMDA and 6 μM of an adamantane derivative, the intensity of the substance effect can be determined as a relative change of the control answer (A/A<sub>c</sub> -A=test answer).</p>
    <p>The results are summarized in the following Table 1:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Compound no.     1-A/Ac    n______________________________________1                0.66 ± 0.05                      142                0.44 ± 0.08                      73                0.58 ± 0.07                      74                0.50 ± 0.11                      55                0.56 ± 0.07                      76                0.38 ± 0.05                      77                0.25 ± 0.04                      118                0.50 ± 0.03                      6PCP              0.50 ± 0.04                      7MK-801           0.60 ± 0.05                      22______________________________________ The values are given as means ± SEM.</pre>
    
    <p>As can be seen from the results, the aminoadamantane derivatives of formula (I) are able to block the NMDA receptor channel as has been described for PCP (Bertolini et al., Neurosci. Lett. 84, 1988, 351-355) and for 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5,10-imine (MK-801) (EP-A 0 264 183).</p>
    <heading>C. Anticonvulsive Effect</heading> <p>4, 12, 36, 108 and 324 mg/kg of the test substance is administered to mice by the intraperitoneal route (5 animals per dose). The supermaximum electroshock test is applied forty (40) minutes after application of the substance to investigate the anti-convulsive potential of the substance. The protected animals are added up over all dosages (score; maximum=25 animals).</p>
    <p>The results are given in the following Table 2.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________       Anticonvulsive        ED<sub>50</sub>Compound no.       action (score)                     Mean    (mg/kg)______________________________________1           18       16       16       15            16.3    162           15       14       12            13.7    304           16       16       11            14.3    245           17       17            17.0    13Standards:PCP         19            19.0     9MK-801      25            25.0    &lt;1______________________________________ The ED<sub>50</sub> values were estimated according to Litchfield, J. T. and Wilcoxon, F., J. Pharmacol. Exp. Therap. 96, 99-113 (1949).</pre>
    
    <p>As can be seen from the above results, aminoadamantane derivatives of formula (I) exhibit a protective effect against electrically induced convulsions. They therefore have an anticonvulsive effect.</p>
    <heading>D. Correlation Between Channel-Blocking and Anticonvulsive Action</heading> <p>The correlation between the action of the tested adamantane derivatives 1-8 at the NMDA receptor channel (in vitro) and the anticonvulsive effect (in vivo) has been tested. For this purpose an xy diagram of both test parameters is plotted. It shows that there is a correlation between the blocking of the NMDA receptor channel and the anticonvulsive action of the adamantanes of formula (I).</p>
    <heading>E. Protection Against Cerebral Ischemia</heading> <p>Both carotid arteries are occluded in rats for 10 minutes. At the same time the blood pressure is reduced to 60-80 mg Hg by withdrawal of blood (Smith et al. 1984, Acta Neurol. Scand. 69: 385, 401). The ischemia is terminated by opening the carotids and reinfusion of the withdrawn blood. After seven days the brains of the test animals are histologically examined for cellular changes in the CA1-CA4 region of the hippocampus, and the percentage of destroyed neurons is determined. The action of test compound No. 1 is determined after a single administration of 5 mg/kg and 20 mg/kg one (1) hour prior to the ischemia.</p>
    <p>The results are summarized in the following Table 3:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________      Test compound no. 1Area  Control    5 mg/kg (n = 5)                          20 mg/kg (n = 6)______________________________________CA1   80.2 ± 1.5            83.0 ± 2.2  53.1 ± 6.1**CA3   3.6 ± 1.1            7.3 ± 1.8  2.7 ± 1.0CA4   1.4 ± 0.4            3.7 ± 1.7  0.6 ± 0.3______________________________________ The values are given in percent of damaged neurons ± SEM. Significance of the mean difference: **p &lt; 0.01 (U test)</pre>
    
    <p>The results show that the reduction of the post-ischemic neuronal brain damage in the CA1 region of the rat hippocampus is statistically significant after the pre-ischemic application of 20 mg/kg of test compound no. 1. Physiological parameters (e.g. blood pressure, body temperature) are not affected by the treatment. Moreover, the results show that the compounds according to formula (I) exhibit a neuroprotective action in cerebral ischemia.</p>
    <p>Essentially the same result is attained by employing the compounds of the other Examples, especially those designated test compounds 2-8.</p>
    <heading>F. Protection Against NMDA-Induced Mortality</heading> <p>It is well known that, subsequent to cerebral ischemia, glutamate and aspartate levels increase massively in the brain. These excitatory aminoacids overstimulate the NMDA-subtype of the glutamate receptor thus leading to delayed neuronal death. A similar pathophysiological situation is obtained when mice are administered intraperitoneally with 200 mg/kg NMDA. This high dose will eventually cause 100% mortality in the animals (Leander et al. 1984, Brain Res. 448; 115-120). We have found that the adamantane derivatives of the present invention are protective against the NMDA-induced mortality.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Compound No. Dose mg/kg Protected Animals______________________________________1            50         8/8        25         6/8        10         3/83            50         6/8        25         4/84            50         7/8        25         5/85            25         5/8______________________________________ In the control animals, to which no adamantane was administered, the mortality was eight (8) animals out of eight (8).</pre>
    
    <heading>G. Displacement of [<sup>3</sup> H] MK-801 Binding in Human Brain Tissue</heading> <p>MK-801 binds to the ion channel associated with the NMDA receptor, as well as TCP does. This binding site is thought to mediate the neuroprotective effects of non-competitive NMDA-antagonists.</p>
    <p>We have investigated whether the adamantane derivatives of the present invention are active at the MK-801 binding site. Tissue from frontal cortex was taken from patients at autopsy and homogenates were prepared. Inhibition of specific [<sup>3</sup> H] MK-801 binding (3 nM) by the test compounds was determined (see e.g. Kornhuber et al. 1989, Eur. J. Pharmacol. 166: 589-590).</p>
    <p>The test compounds were highly potent in displacing MK-801 binding, thus indicating a specific interaction with the NMDA receptor channel and predicting neuroprotective properties.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________           KiCompound No.    nM______________________________________1               5363               5984               1895               1607______________________________________</pre>
    
    <p>wherein K<sub>i</sub> is the inhibition constant and nM is nanomoles per liter. Mean values from triplicate experiments are given ± S.E.M.</p>
    <p>The inhibition constant Ki is approximately equal to the concentration of the adamantane in nM required to displace 50% of the MK-801 specifically bound to the receptor. In this regard, memantine (Compound No. 1) was found to be the most potent compound subjected to this test, when compared with thirteen (13) other clinically-used and centrally-acting drugs, as reported in the foregoing publication.</p>
    <p>The invention is further described by the following illustrative examples, which are not to be construed as limiting:</p>
    <heading>EXAMPLE 1</heading> <heading>Injectable Solution</heading> <p>For preparing a 0.5% solution, dissolve 0.5% active ingredient and 0.8% sodium chloride (DAB 9) in doubly distilled water. Filter the solution through an antimicrobial filter, fill into 2-ml ampoules and sterilize for 20 minutes at 120° C. in an autoclave.</p>
    <heading>EXAMPLE 2</heading> <heading>Solution</heading> <p>Dissolve 1% of active agent in demineralized water. Filter the solution before filling.</p>
    <heading>EXAMPLE 3</heading> <heading>Tablets</heading> <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________ 1 tablet contains:______________________________________Active ingredient       10.0   mgLactose                 67.5   mgMicrocrystalline cellulose                   18.0   mgTalc                    4.5    mg                   100.0  mg______________________________________</pre>
    
    <p>The substances are mixed and the mixture compressed into 100-mg tablets in a direct tableting procedure without granulation.</p>
    <heading>EXAMPLE 4</heading> <heading>Coated Tablets</heading> <p>Prepare 6-mm tablet cores of 100 mg as described under "Tablets". Coat the tablets in a sugar-coating process by coating the core with a sugar suspension first, followed by staining with a colored syrup and polishing.</p>
    <p>The tablet coating consists of:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Sugar                   65.0   mgTalc                    39.0   mgCalcium carbonate       13.0   mgGum arabic              6.5    mgCorn starch             3.7    mgShellac                 1.1    mgPolyethylene glycol 6000                   0.2    mgMagnesia usta           1.3    mgDye                     0.2    mg                   130.0  mg______________________________________ Total tablet weight: 230 mg</pre>
    
    <heading>EXAMPLE 5</heading> <p>For preparing a 0.01% infusion solution, dissolve 0.01% of active ingredient and 5% levulose in doubly-distilled water. Filter the solution through an antimicrobial filter, fill into 500-ml infusion bottles, and sterilize.</p>
    <p>The example provides 50 mg of active substance per single dose.</p>
    <heading>EXAMPLE 6</heading> <heading>Synthesis of 1-Amino-3-isopropyl Adamantane Hydrochloride (Test Compound No. 3)</heading> <heading>A. Preparation of Adamantane Methyl Carboxylate (I)</heading> <p>Stir 1.0 mol of adamantane carboxylic acid in 600 ml of methanol. Under ice cooling, drop 1.53 mol of acetyl chloride into the solution within 1 h. Remove the ice bath, and allow the reaction mixture to reach room temperature. Subsequently, heat for 3 hrs under reflux. Evaporate the reaction mixture to dryness under vacuum and distill. (Yield: 97%).</p>
    <heading>B. Preparation of Isopropyl Adamantane (II)</heading> <p>Introduce 0.5 mol of magnesium chips into 50 ml of absolute ether, and drop 0.5 mol of methyl iodide into the solution under moisture-free conditions until the ether boils. Subsequently, heat in a water bath until the magnesium has completely dissolved. Into this solution at room temperature drop 0.2 mol of adamantane methyl carboxylate in absolute ether. Then heat to reflux for 3 hours. After cooling, hydrolize with ice and mix with ammonium chloride solution until the precipitate has dissolved. Separate the ether phase, wash the aqueous phase with 2 portions of ether, and wash the combined organic phases with sodium bicarbonate solution. Then dry and evaporate to dryness under vacuum. (Yield: 93%).</p>
    <heading>C. Preparation of Isopropene Adamantane (III)</heading> <p>Stir 0.25 mol of isopropyl adamantane (II) in 500 ml acetic anhydride for 12 hours at 160° C. Subsequently, pour the reaction mixture onto 1 liter of ice water and extract with ether. Dry the combined organic phases with magnesium sulfate, filter, and evaporate to dryness under vacuum. Distill the residue under vacuum. (Yield: 66%).</p>
    <heading>D. Preparation of Isopropyl Adamantane (IV)</heading> <p>Dissolve 0.074 mol of adamantyl isopropene (III) in 100 ml of absolute ethanol. Add 4 g of palladium (5% on activated carbon) and hydrate under stirring for 24 hrs at room temperature. Subsequently, filter off the catalyst, and remove the solvent under vacuum. (Yield: 91%).</p>
    <heading>E. Preparation of 1-Bromo-3-isopropyl Adamantane (V)</heading> <p>Mix 0.034 mol of isopropyl adamantane (IV) with a ten times excess of bromine (0.33 mol). Heat slowly and stir under reflux for 4 h. Subsequently, allow to cool and pour onto ice water. Decompose the excess bromine with sodium sulfite until the aqueous solution has discolored. Then extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 83%).</p>
    <heading>F. Preparation of 1-N-formyl-3-isopropyl Adamantane (VI)</heading> <p>Heat 0.028 mol of 1-bromo-3-isopropyl adamantane (V) with 40 ml of formamide to reflux for 12 hrs. After cooling, pour the reaction mixture onto water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness under vacuum. (Yield: 82%).</p>
    <heading>G. Preparation of 1-Amino-3-isopropyl Adamantane Hydrochloride</heading> <p>Mix 0.023 mol of 1-N-formyl-3-isopropyl adamantane (VI) with 100 ml of 15% hydrochloric acid and heat to boiling for 24 hrs. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 57%).</p>
    <heading>EXAMPLE 7</heading> <heading>Synthesis of 1-Amino-3-cyclohexyl Adamantane Hydrochloride (Test Compound No. 7)</heading> <heading>A. Preparation of 1-Phenyl Adamantane (I)</heading> <p>Heat 0.068 mol of iron(III) chloride to boiling in 20 ml of absolute benzene. Drop 0.0186 mol of 1-bromo-adamantane, dissolved in 30 ml of absolute benzene, to the solution. Then heat to boiling for 3 hrs. After cooling, pour the reaction mixture onto ice/hydrochloric acid, separate the organic phase, and extract the aqueous phase with two portions of benzene. Wash the combined organic phases with water, dry with calcium chloride, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 80%).</p>
    <heading>B. Preparation of 1-Hydroxy-3-phenyl Adamantane (II)</heading> <p>To a solution of 0.03 mol chromiumtrioxide in 20 ml glacial acetic acid and 20 ml acetic anhydride, add 0.0095 mol of 1-phenyl adamantane at 0° C. and stir for 24 hours at 4° C. Pour the reaction mixture onto water and extract with three portions of pentane. Wash the organic phase with saturated sodium chloride solution, dry over magnesium sulfate, filter and evaporate to dryness under vacuum. Hydrolize the residue with 20 ml of 2N NaOH and 50 ml of methanol. Subsequently, remove the methanol under vacuum and dilute the residue with water. Then extract with three portions of ether. Dry the organic phase, filter and evaporate to dryness under vacuum. Recrystallize the residue from cyclohexane. (Yield: 50%).</p>
    <p>Ref.: H. Stetter, M. Schwarz, A. Hirschhorn, Chem. Ber. (1959), 92, 1629-35.</p>
    <heading>C. Preparation of 1-Bromo-3-phenyl Adamantane (III)</heading> <p>Stir 0.03 mol of 3-phenyl adamantanol (II) with 100 ml of 40% HBr in glacial acetic acid for 20 min at 60° C. and 30 min at room temperature. Subsequently, dilute the reaction mixture with water and extract with ether. Wash the combined organic extracts with sodium chloride solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 68%).</p>
    <p>Ref.: W. Fischer, C. A. Grog, Helvetica Chim. Acta (1976), 59, 1953.</p>
    <heading>D. Preparation of 1-N-formyl-3-phenyl Adamantane (IV)</heading> <p>Heat 0.03 mol of 1-bromo-3-phenyl adamantane (III) with 50 ml of formamide for 12 hrs to reflux. After cooling, pour the reaction mixture onto water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness under vacuum. (Yield: 80%).</p>
    <heading>E. Preparation of 1-Amino-3-phenyl Adamantane Hydrochloride (V)</heading> <p>Heat 0.02 mol of 1-N-formyl-3-phenyl adamantane (IV) with 100 ml of 15% hydrochloric acid at reflux for 24 hours. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 60%).</p>
    <heading>F. Preparation of 1-Amino-3-cyclohexyl Adamantane (VI)</heading> <p>Dissolve 0.011 mol of 1-amino-3-phenyl adamantane (V) in 150 ml glacial acetic acid, mix with 0.3 g of platinum oxide (1% on activated carbon) and hydrate in a Parr apparatus at 35° C. at a hydrogen pressure of 3 bar. Subsequently, remove the catalyst by filtration and evaporate the filtrate to dryness. Take up the residue in methanol and precipitate the product with ether. Suck off and dry. (Yield: 70%).</p>
    <heading>EXAMPLE 8</heading> <heading>Synthesis of 1-Amino-3,5-dimethyl-7-ethyl Adamantane Hydrochloride (Test Compound No. 8)</heading> <heading>A. Preparation of 1-Bromo-3,5-dimethyl Adamantane (I)</heading> <p>Mix 0.5 mol of 1,3-dimethyl adamantane with a ten times excess of bromine (5 mol). Slowly heat and stir for 4 hrs under reflux. Subsequently, allow to cool and pour onto ice water. Decompose the excess bromine with sodium sulfite until discoloration of the aqueous solution. Then extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 83%).</p>
    <heading>B. Preparation of 1-(2-Bromoethyl)-3,5-dimethyl Adamantane (II)</heading> <p>Mix 1.4 mol of 1-bromo-3,5-dimethyl adamantane (I) in hexane with 0.6 mol of aluminum bromide at -75° C. Subsequently, pass ethylene through the solution for 20-30 minutes, stir for 5 min., and pour the reaction mixture onto ice water. Extract with ether, dry the organic phase and evaporate to dryness. Recrystallize the residue from methanol. (Yield: 48%).</p>
    <heading>C. Preparation of 1,3-Dimethyl-5-ethyl Adamantane (III)</heading> <p>Dissolve 0.5 mol of 1-(2-bromoethyl)-3,5-dimethyl adamantane (II) in toluene, mix with 0.55 mol of sodium-bis(2-methoxy-ethoxy)dihydro aluminate, and heat to boiling for 3 hrs. After hydrolysis, separate the organic phase, dry with magnesium sulfate, and evaporate to dryness under vacuum. Purify the residue by vacuum distillation. (Yield: 86%).</p>
    <heading>D. Preparation of 1-Bromo-3,5-dimethyl-7-ethyl Adamantane (IV)</heading> <p>Mix 0.4 mol of 1,3-dimethyl-5-ethyl adamantane (III) with a ten times excess of bromine (4 mol). Heat slowly and stir for 4 hrs under reflux. Subsequently allow to cool and pour onto ice water. Decompose the excess bromine with sodium sulfite until discolouration of the aqueous solution. Then extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 86%).</p>
    <heading>E. Preparation of 1-N-formyl-3,5-dimethyl-7-ethyl Adamantane (V)</heading> <p>Heat 0.2 mol of 1-bromine-3,5-dimethyl-7-ethyl adamantane (IV) with 150 ml of formamide at reflux for 12 hrs. After cooling, pour the reaction mixture onto water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness under vacuum. (Yield: 82%).</p>
    <heading>F. Preparation of 1-Amino-3,5-dimethyl-7-ethyl Adamantane Hydrochloride (VI)</heading> <p>Mix 0.2 mol of 1-N-formyl-3,5-dimethyl-7-ethyl adamantane (V) with 100 ml of 15% hydrochloric acid and heat to boiling for 24 hrs. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 57%).</p>
    <heading>EXAMPLE 9</heading> <heading>Synthesis of 1-N-methylamino-3,5-dimethyl Adamantane (Test Compound No. 5)</heading> <p>Dissolve 0.1 mol of the appropriately substituted amino adamantane (1-amino-3,5-dimethyl adamantane) with 0.15 mol of chloromethyl formate and potassium carbonate in acetone and heat to reflux for 8 hrs. After cooling, filter the solution, remove the solvent and dry the residue. Mix the raw product (0.05 mol) with 0.1 mol of sodium-bis-(2-methoxy-ethoxy)-dihydro aluminate in toluene and heat at reflux for 3 hrs. After cooling, hydrolize with dilute HCl, dry the organic phase and evaporate to dryness. Purify the raw material by distillation.</p>
    <heading>EXAMPLE 10</heading> <heading>Synthesis of 1-Amino-3-ethyl-5-phenyl Adamantane</heading> <heading>A. Preparation of 1-Bromo-3-ethyl Adamantane (I)</heading> <p>Mix 0.034 mol of ethyl adamantane with a ten times excess of bromine (0.33 mol). Heat slowly and stir under reflux for 4 hrs. Then allow to cool and pour onto ice water. Decompose the excess bromine with sodium sulfite until discoloration of the aqueous solution. Subsequently extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 83%).</p>
    <heading>B. Preparation of 1-Ethyl-3-phenyl Adamantane (II)</heading> <p>Heat 0.068 mol of iron(III) chloride in 20 ml of absolute benzene to boiling. Drop 0.0186 mol of 1-bromo-3-ethyl adamantane (I), dissolved in 30 ml of absolute benzene, into the solution. Then heat at reflux for 3 hrs. After cooling, pour the reaction mixture onto ice/hydrochloric acid, separate the organic phase, and extract with two portions of benzene. Wash the combined organic phases with water, dry with calcium chloride, filter and evaporate to dryness. Recrystallize the residue from methanol. (Yield: 80%).</p>
    <heading>C. Preparation of 1-Ethyl-3-hydroxy-5-phenyl Adamantane (III)</heading> <p>To a solution of 0.03 mol of chromiumtrioxide, in 20 ml glacial acetic acid and 20 ml acetic anhydride, add 0.0095 mol of 1-ethyl-3-phenyl adamantane (II) at 0° C. and stir for 24 hours at 4° C. Pour the reaction mixture into water and extract with three portions of pentane. Wash the organic phase with saturated sodium chloride solution, dry over magnesium sulfate, filter and evaporate to dryness under vacuum. Hydrolize the residue with 20 ml of 2N NaOH and 50 ml of methanol. Remove the methanol under vacuum and dilute the residue with water. Then extract with three portions of ether. Dry the organic phase, filter and evaporate to dryness under vacuum. Recrystallize the residue from cyclohexane. (Yield: 50%).</p>
    <p>Ref.: H. Stetter, M. Schwarz, A. Hirschhorn, Chem. Ber. (1959), 92, 1629-35.</p>
    <heading>D. Preparation of 1-Bromo-3-ethyl-5-phenyl Adamantane (IV)</heading> <p>Stir 0.03 mol of 1-ethyl-3-hydroxy-5-phenyl adamantane (III) with 100 ml of 40% HBr in glacial acetic acid for 20 min at 60° C. and for 30 min at room temperature. Subsequently dilute the reaction mixture with water and extract with ether. Wash the combined organic extracts with sodium chloride solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 68%).</p>
    <p>Ref.: W. Fischer, C. A. Grog, Helvetica Chim. Acta (1976), 59, 1953.</p>
    <heading>E. Preparation of 1-N-formyl-3-ethyl-5-phenyl Adamantane (V)</heading> <p>Heat 0.03 mol of 1-ethyl-3-hydroxy-5-phenyl adamantane (IV) with 50 ml of formamide for 12 hrs at reflux. After cooling, pour the reaction mixture into water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness. (Yield: 80%).</p>
    <heading>F. Preparation of 1-Amino-3-ethyl-5-phenyl Adamantane Hydrochloride (VI)</heading> <p>Heat 0.02 mol of 1-N-formyl-3-ethyl-5-phenyl adamantane (V) with 100 ml of 15% hydrochloric acid for 24 hrs at reflux. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 60%).</p>
    <p>It is thus seen that certain adamantane derivatives, some of which are novel, have been provided for the prevention and treatment of cerebral ischemia, and that pharmaceutical compositions embodying such an adamantane derivative have been provided for use in the prevention and treatment of cerebral ischemia, the amount of the said adamantane derivative provided in either case being a cerebral ischemia-alleviating or preventive amount.</p>
    <p>Various modifications and equivalents will be apparent to one skilled in the art and may be made in the compounds, compositions, methods, and procedures of the present invention without departing from the spirit or scope thereof, and it is therefore to be understood that the invention is to be limited only by the full scope which can be legally attributed to the appended claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0227410A2?cl=en">EP0227410A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 16, 1986</td><td class="patent-data-table-td patent-date-value">Jul 1, 1987</td><td class="patent-data-table-td ">Takeda Chemical Industries, Ltd.</td><td class="patent-data-table-td ">Peptide derivatives, their production and use</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Berkow, R.; The Merck Manual. 15, pp. 1336 1340 (1987).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Berkow, R.; The Merck Manual. 15, pp. 1336-1340 (1987).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hamoen, A. M.; British Medical Journal. 3, (5874), pp. 272 273 (1973).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hamoen, A. M.; British Medical Journal. 3, (5874), pp. 272-273 (1973).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hossman, K. A.; Critical Care Medicine. 16 (10), pp. 964 971 (1988).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hossman, K. A.; Critical Care Medicine. 16 (10), pp. 964-971 (1988).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hoyer, S.; Aging. 11, pp. 158 166 (1988).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hoyer, S.; Aging. 11, pp. 158-166 (1988).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kinomota, H. et al.; No Skinkei Geka, 12 (1), pp. 37 45 (1984).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kinomota, H. et al.; No Skinkei Geka, 12 (1), pp. 37-45 (1984).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Krieglstein, J., Weber, J. in Oxygen Transport to Tissue, VIII, Longmuir, I. S., Editor; Plenum Publishing Corporation; pp. 243 253 (1986).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Krieglstein, J., Weber, J. in Oxygen Transport to Tissue, VIII, Longmuir, I. S., Editor; Plenum Publishing Corporation; pp. 243-253 (1986).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Marcy, R. et al.; J. Pharmacol. 13 (1), pp. 163 164 (1982).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marcy, R. et al.; J. Pharmacol. 13 (1), pp. 163-164 (1982).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1268 1270 (1982).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1268-1270 (1982).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1271 1273 (1982).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miltner, F. O.; Arzneimittelforschung. 32 (10), pp. 1271-1273 (1982).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Miura, Y. et al.; Japan. J. Pharmacol. 39, pp. 443 451 (1986).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miura, Y. et al.; Japan. J. Pharmacol. 39, pp. 443-451 (1986).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Otomo, E; Japan. J. Neuropsychopharmacol. 4/2, pp. 113 119 (1982).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Otomo, E; Japan. J. Neuropsychopharmacol. 4/2, pp. 113-119 (1982).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sugio, K. et al.; Japan. J. Pharmacol. 47, pp. 327 329 (1988).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sugio, K. et al.; Japan. J. Pharmacol. 47, pp. 327-329 (1988).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5334618">US5334618</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 3, 1992</td><td class="patent-data-table-td patent-date-value">Aug 2, 1994</td><td class="patent-data-table-td ">The Children&#39;s Medical Center Corporation</td><td class="patent-data-table-td ">Administering amantadine or derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5382601">US5382601</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 23, 1993</td><td class="patent-data-table-td patent-date-value">Jan 17, 1995</td><td class="patent-data-table-td ">Merz + Co. Gmbh &amp; Co.</td><td class="patent-data-table-td ">Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5506231">US5506231</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 21, 1993</td><td class="patent-data-table-td patent-date-value">Apr 9, 1996</td><td class="patent-data-table-td ">The Children&#39;s Medical Center Corporation</td><td class="patent-data-table-td ">Administering an antagonist of excitatory amino acids to reduce central nervous system disorder caused by human immunodeficiency virus infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5614560">US5614560</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 11, 1995</td><td class="patent-data-table-td patent-date-value">Mar 25, 1997</td><td class="patent-data-table-td ">Children&#39;s Medical Center Corporation</td><td class="patent-data-table-td ">Method of preventing NMDA receptor-mediated neuronal damage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5747545">US5747545</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 22, 1995</td><td class="patent-data-table-td patent-date-value">May 5, 1998</td><td class="patent-data-table-td ">The Children&#39;s Medical Center Corporation</td><td class="patent-data-table-td ">Method of preventing NMDA receptor complex-mediated Neuronal damage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5866585">US5866585</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 22, 1997</td><td class="patent-data-table-td patent-date-value">Feb 2, 1999</td><td class="patent-data-table-td ">Synchroneuron, Llc</td><td class="patent-data-table-td ">Methods of treating tardive dyskinesia using NMDA receptor antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5952389">US5952389</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 13, 1998</td><td class="patent-data-table-td patent-date-value">Sep 14, 1999</td><td class="patent-data-table-td ">Synchroneuron</td><td class="patent-data-table-td ">Methods of treating tardive dyskinesia and other movement disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6057373">US6057373</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 4, 1999</td><td class="patent-data-table-td patent-date-value">May 2, 2000</td><td class="patent-data-table-td ">Synchroneuron, Llc</td><td class="patent-data-table-td ">Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6066652">US6066652</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 31, 1996</td><td class="patent-data-table-td patent-date-value">May 23, 2000</td><td class="patent-data-table-td ">Tinnitus Forschungs-Und Entwicklungs Gmbh</td><td class="patent-data-table-td ">Method for treating diseases of the inner ear using adamantane derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6294583">US6294583</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 1998</td><td class="patent-data-table-td patent-date-value">Sep 25, 2001</td><td class="patent-data-table-td ">Synchroneuron, Llc</td><td class="patent-data-table-td ">For threrapy of tic disorders, tourette&#39;s syndrome, and blepharospasm, and other focal dystonias</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7145037">US7145037</a></td><td class="patent-data-table-td patent-date-value">Sep 1, 2004</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Rotta Research Laboraturium S.P.A.</td><td class="patent-data-table-td ">Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7326730">US7326730</a></td><td class="patent-data-table-td patent-date-value">Nov 17, 2005</td><td class="patent-data-table-td patent-date-value">Feb 5, 2008</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Aminoadamantane derivatives as therapeutic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7355080">US7355080</a></td><td class="patent-data-table-td patent-date-value">Dec 19, 2003</td><td class="patent-data-table-td patent-date-value">Apr 8, 2008</td><td class="patent-data-table-td ">Shanghai Institute Of Pharmaceutical Industry</td><td class="patent-data-table-td ">Reacting 1-bromo-3,5-dimethyl adamantane and urea/formic acid, with formic acid also acting as the solvent; hydrolyzing with aqueous inorganic acid; alkalifying, and extracting and acidifying with hydrochloric acid; performed in homogeneous phase under mild conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7405324">US7405324</a></td><td class="patent-data-table-td patent-date-value">May 10, 2006</td><td class="patent-data-table-td patent-date-value">Jul 29, 2008</td><td class="patent-data-table-td ">A.M.S.A. Anonima Materie Sintetiche E. Afini S.P.A.</td><td class="patent-data-table-td ">chemical preparing acetamido adamantanes intermediate first from halogen adamantane, use for making N-methyl-D-aspartic acid (NDMA) receptor antagonist, treating Parkinson&#39;s Disease, central nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7456224">US7456224</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 21, 2004</td><td class="patent-data-table-td patent-date-value">Nov 25, 2008</td><td class="patent-data-table-td ">Forest Laboratories Holdings, Ltd.</td><td class="patent-data-table-td ">Memantine derivatives (5 - 20 mg per day); methylaspartic receptor antagonist; Pervasive Developmental Disorders (PDD); sensory integration problems, verbal and non-verbal communication, social interactions, and leisure or play activities; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7462743">US7462743</a></td><td class="patent-data-table-td patent-date-value">Jan 11, 2006</td><td class="patent-data-table-td patent-date-value">Dec 9, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Fine Chemicals S.R.L.</td><td class="patent-data-table-td ">Polymorphs of memantine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7498361">US7498361</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 27, 2001</td><td class="patent-data-table-td patent-date-value">Mar 3, 2009</td><td class="patent-data-table-td ">Synchroneuron, Llc</td><td class="patent-data-table-td ">Methods of treating tardive dyskinesia and other movement disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7619007">US7619007</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Provides pharmaceutical compositions that are administered so as to deliver to a subject, an amount of an NMDAr antagonist that is high enough to treat symptoms or damaging effects of an underlying disease while avoiding undesirable side effects, particularly CNS side effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7745493">US7745493</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 25, 2006</td><td class="patent-data-table-td patent-date-value">Jun 29, 2010</td><td class="patent-data-table-td ">Synchroneuron, Llc</td><td class="patent-data-table-td ">acamprosate; Parkinson&#39;s disease or Huntington&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795468">US7795468</a></td><td class="patent-data-table-td patent-date-value">Dec 6, 2002</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Chevron U.S.A. Inc.</td><td class="patent-data-table-td ">Functional groups covalently attached with higher diamondoid nucleus, applications as chemical intermediates, materials for nanotechnology, biologically reactive materials and coatings</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8013018">US8013018</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 2007</td><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">Astellas Pharma Inc.</td><td class="patent-data-table-td ">Aminoindane derivative or salt thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039009">US8039009</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2005</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Forest Laboratories Holdings Limited</td><td class="patent-data-table-td ">Modified release formulations of memantine oral dosage forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058291">US8058291</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2006</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods and compositions for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8138375">US8138375</a></td><td class="patent-data-table-td patent-date-value">Feb 20, 2007</td><td class="patent-data-table-td patent-date-value">Mar 20, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Method for producing 1-formamido-3,5-dimethyladamantane</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8168209">US8168209</a></td><td class="patent-data-table-td patent-date-value">Jul 30, 2009</td><td class="patent-data-table-td patent-date-value">May 1, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method and composition for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8173708">US8173708</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2010</td><td class="patent-data-table-td patent-date-value">May 8, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method and composition for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8283379">US8283379</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2010</td><td class="patent-data-table-td patent-date-value">Oct 9, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods and compositions for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8293794">US8293794</a></td><td class="patent-data-table-td patent-date-value">Apr 2, 2010</td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods and compositions for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329752">US8329752</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Composition for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8338485">US8338485</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Dec 25, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8338486">US8338486</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Dec 25, 2012</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8362085">US8362085</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8426472">US8426472</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 2011</td><td class="patent-data-table-td patent-date-value">Apr 23, 2013</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method and composition for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8436209">US8436209</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2009</td><td class="patent-data-table-td patent-date-value">May 7, 2013</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Process for the manufacture of memantine and intermediate product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8481016">US8481016</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">Kao Corporation</td><td class="patent-data-table-td ">Method for inhibition of potential-dependent cation channel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8557800">US8557800</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2011</td><td class="patent-data-table-td patent-date-value">Oct 15, 2013</td><td class="patent-data-table-td ">Apogee Biotechnology Corporation</td><td class="patent-data-table-td ">Sphingosine kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8580858">US8580858</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2012</td><td class="patent-data-table-td patent-date-value">Nov 12, 2013</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions for the treatment of CNS-related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8598233">US8598233</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2013</td><td class="patent-data-table-td patent-date-value">Dec 3, 2013</td><td class="patent-data-table-td ">Adamas Pharmacueticals, Inc.</td><td class="patent-data-table-td ">Method for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8648059">US8648059</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 12, 2009</td><td class="patent-data-table-td patent-date-value">Feb 11, 2014</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8741343">US8741343</a></td><td class="patent-data-table-td patent-date-value">Dec 2, 2010</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method of administering amantadine prior to a sleep period</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20130045177">US20130045177</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td patent-date-value">Feb 21, 2013</td><td class="patent-data-table-td ">Hiroko Takatoku</td><td class="patent-data-table-td ">Method for Inhibition of Potential-Dependent Cation Channel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE19510189A1?cl=en">DE19510189A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 21, 1995</td><td class="patent-data-table-td patent-date-value">Sep 26, 1996</td><td class="patent-data-table-td ">Hartmut Dr Goebel</td><td class="patent-data-table-td ">Verwendung von Amantadin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1512679A1?cl=en">EP1512679A1</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2004</td><td class="patent-data-table-td patent-date-value">Mar 9, 2005</td><td class="patent-data-table-td ">Rotta Research Laboratorium S.P.A.</td><td class="patent-data-table-td ">Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1721888A1?cl=en">EP1721888A1</a></td><td class="patent-data-table-td patent-date-value">May 9, 2006</td><td class="patent-data-table-td patent-date-value">Nov 15, 2006</td><td class="patent-data-table-td ">A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A.</td><td class="patent-data-table-td ">Process for synthesising aminoadamantanes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1904439A2?cl=en">EP1904439A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 15, 2006</td><td class="patent-data-table-td patent-date-value">Apr 2, 2008</td><td class="patent-data-table-td ">Apogee Biothechnology Corporation</td><td class="patent-data-table-td ">Sphingosine kinase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1999100A1?cl=en">EP1999100A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by third party"> †</span></td><td class="patent-data-table-td patent-date-value">Mar 27, 2007</td><td class="patent-data-table-td patent-date-value">Dec 10, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Fine Chemicals S.R.L.</td><td class="patent-data-table-td ">Process for preparing memantine hydrochloride substantially free of impurities</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2085398A1?cl=en">EP2085398A1</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2008</td><td class="patent-data-table-td patent-date-value">Aug 5, 2009</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Pyrazolopyrimidines, a process for their preparation and their use as medicine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2090576A1?cl=en">EP2090576A1</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 2008</td><td class="patent-data-table-td patent-date-value">Aug 19, 2009</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp;amp; Co.KGaA</td><td class="patent-data-table-td ">6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2103597A1?cl=en">EP2103597A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2008</td><td class="patent-data-table-td patent-date-value">Sep 23, 2009</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp;amp; Co.KGaA</td><td class="patent-data-table-td ">Process for the manufacture of memantine and intermediate product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2111858A1?cl=en">EP2111858A1</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2008</td><td class="patent-data-table-td patent-date-value">Oct 28, 2009</td><td class="patent-data-table-td ">EPFL Ecole Polytechnique Fédérale de Lausanne</td><td class="patent-data-table-td ">Novel treatment for alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2138173A1?cl=en">EP2138173A1</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2008</td><td class="patent-data-table-td patent-date-value">Dec 30, 2009</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp;amp; Co.KGaA</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising aminoadamantane derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2243475A1?cl=en">EP2243475A1</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2006</td><td class="patent-data-table-td patent-date-value">Oct 27, 2010</td><td class="patent-data-table-td ">Adamas Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Combination of memantine and donepezil for treatment of CNS disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2260839A2?cl=en">EP2260839A2</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2003</td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2260844A1?cl=en">EP2260844A1</a></td><td class="patent-data-table-td patent-date-value">May 27, 2004</td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2289489A2?cl=en">EP2289489A2</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2004</td><td class="patent-data-table-td patent-date-value">Mar 2, 2011</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Compositions comprising cyclohexylamines and aminoadamantanes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2295439A1?cl=en">EP2295439A1</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2007</td><td class="patent-data-table-td patent-date-value">Mar 16, 2011</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2343057A1?cl=en">EP2343057A1</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td patent-date-value">Jul 13, 2011</td><td class="patent-data-table-td ">Neuromolecular Pharmaceuticals, Inc</td><td class="patent-data-table-td ">Method and composition for administering an NMDA receptor antagonist to a subject</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2397122A2?cl=en">EP2397122A2</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2005</td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Formulations of neramexane dosage forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2420235A1?cl=en">EP2420235A1</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Feb 22, 2012</td><td class="patent-data-table-td ">Medivation Neurology, Inc.</td><td class="patent-data-table-td ">Methods and combination therapies for treating alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2601937A1?cl=en">EP2601937A1</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2005</td><td class="patent-data-table-td patent-date-value">Jun 12, 2013</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Drinkable immediate release tablet made with direct compression of memantine or neramexane</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2623099A1?cl=en">EP2623099A1</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2005</td><td class="patent-data-table-td patent-date-value">Aug 7, 2013</td><td class="patent-data-table-td ">Neuromolecular Pharmaceuticals, Inc</td><td class="patent-data-table-td ">Composition and method for treating neurological disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2650284A1?cl=en">EP2650284A1</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2012</td><td class="patent-data-table-td patent-date-value">Oct 16, 2013</td><td class="patent-data-table-td ">Merz Pharma GmbH &amp; Co. KGaA</td><td class="patent-data-table-td ">Heterocyclic derivatives as metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992017168A1?cl=en">WO1992017168A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 3, 1992</td><td class="patent-data-table-td patent-date-value">Oct 15, 1992</td><td class="patent-data-table-td ">Childrens Medical Center</td><td class="patent-data-table-td ">Method of preventing nmda receptor-mediated neuronal damage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994005275A1?cl=en">WO1994005275A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 3, 1993</td><td class="patent-data-table-td patent-date-value">Mar 17, 1994</td><td class="patent-data-table-td ">Childrens Medical Center</td><td class="patent-data-table-td ">Method of preventing nmda receptor-mediated neuronal damage</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003064372A1?cl=en">WO2003064372A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 27, 2003</td><td class="patent-data-table-td patent-date-value">Aug 7, 2003</td><td class="patent-data-table-td ">Toby Jonathan Blench</td><td class="patent-data-table-td ">2-adamantylalkylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004009062A2?cl=en">WO2004009062A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 17, 2003</td><td class="patent-data-table-td patent-date-value">Jan 29, 2004</td><td class="patent-data-table-td ">Khalid Iqbal</td><td class="patent-data-table-td ">NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005023753A1?cl=en">WO2005023753A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 19, 2003</td><td class="patent-data-table-td patent-date-value">Mar 17, 2005</td><td class="patent-data-table-td ">Mengya Ge</td><td class="patent-data-table-td ">A method of preparing memantine hydrochloride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005079779A1?cl=en">WO2005079779A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 22, 2004</td><td class="patent-data-table-td patent-date-value">Sep 1, 2005</td><td class="patent-data-table-td ">Pradeep Banarjee</td><td class="patent-data-table-td ">THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006096194A2?cl=en">WO2006096194A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 16, 2005</td><td class="patent-data-table-td patent-date-value">Sep 14, 2006</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co Kgaa</td><td class="patent-data-table-td ">Drinkable immediate release tablet made with direct compression of memantine or neramexane</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006122238A1?cl=en">WO2006122238A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 11, 2006</td><td class="patent-data-table-td patent-date-value">Nov 16, 2006</td><td class="patent-data-table-td ">Mukunda Reddy Jambula</td><td class="patent-data-table-td ">Process for preparing memantine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008051599A2?cl=en">WO2008051599A2</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">May 2, 2008</td><td class="patent-data-table-td ">Medivation Inc</td><td class="patent-data-table-td ">Combination therapies for treating alzheimer&#39;s disease using i. a. dimebon and dolepezil</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009119982A2?cl=en">WO2009119982A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 9, 2009</td><td class="patent-data-table-td patent-date-value">Oct 1, 2009</td><td class="patent-data-table-td ">Nanodiamond, Inc.</td><td class="patent-data-table-td ">Adamantine derivative for inhibiting toxicity of amyloid oligomer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009128058A1?cl=en">WO2009128058A1</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2009</td><td class="patent-data-table-td patent-date-value">Oct 22, 2009</td><td class="patent-data-table-td ">UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al</td><td class="patent-data-table-td ">Psycho-pharmaceuticals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010112221A1?cl=en">WO2010112221A1</a></td><td class="patent-data-table-td patent-date-value">Mar 29, 2010</td><td class="patent-data-table-td patent-date-value">Oct 7, 2010</td><td class="patent-data-table-td ">Synthon B.V.</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising memantine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011015343A1?cl=en">WO2011015343A1</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2010</td><td class="patent-data-table-td patent-date-value">Feb 10, 2011</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011127235A1?cl=en">WO2011127235A1</a></td><td class="patent-data-table-td patent-date-value">Apr 7, 2011</td><td class="patent-data-table-td patent-date-value">Oct 13, 2011</td><td class="patent-data-table-td ">Eisai Inc.</td><td class="patent-data-table-td ">Combination therapy for the treatment of dementia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012048871A1?cl=en">WO2012048871A1</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2011</td><td class="patent-data-table-td patent-date-value">Apr 19, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Memantine for improving cognitive performance in subjects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012052451A1?cl=en">WO2012052451A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td patent-date-value">Apr 26, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012055945A1?cl=en">WO2012055945A1</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2011</td><td class="patent-data-table-td patent-date-value">May 3, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Indole derivatives and process for their preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012085166A1?cl=en">WO2012085166A1</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012085167A1?cl=en">WO2012085167A1</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012101653A2?cl=en">WO2012101653A2</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td patent-date-value">Aug 2, 2012</td><td class="patent-data-table-td ">Cadila Healthcare Limited</td><td class="patent-data-table-td ">Modified release pharmaceutical compositions memantine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012145981A1?cl=en">WO2012145981A1</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2011</td><td class="patent-data-table-td patent-date-value">Nov 1, 2012</td><td class="patent-data-table-td ">Liaoning Lifeng Scientific &amp; Technology Development Company Ltd.</td><td class="patent-data-table-td ">Adamantane or adamantane-like compounds as antitumor agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012152854A1?cl=en">WO2012152854A1</a></td><td class="patent-data-table-td patent-date-value">May 10, 2012</td><td class="patent-data-table-td patent-date-value">Nov 15, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Metabotropic glutamate receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012172093A1?cl=en">WO2012172093A1</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 2012</td><td class="patent-data-table-td patent-date-value">Dec 20, 2012</td><td class="patent-data-table-td ">Merz Pharma Gmbh &amp; Co. Kgaa</td><td class="patent-data-table-td ">Dihydroindolizine derivate as metabotropic glutamate receptor modulators</td></tr></table><div class="patent-section-footer">* Cited by examiner, † Cited by third party</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S212010">514/212.01</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S325000">514/325</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S662000">514/662</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S359000">514/359</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025000000">A61P25/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A47F0007080000">A47F7/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0009000000">A61P9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031130000">A61K31/13</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0025280000">A61P25/28</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07C2103/74">C07C2103/74</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07C211/38">C07C211/38</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07C2101/14">C07C2101/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=7VwxBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/13">A61K31/13</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/13</span>, <span class="nested-value">C07C211/38</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Feb 17, 2011</td><td class="patent-data-table-td ">356</td><td class="patent-data-table-td ">Patent term extension under 35 u.s.c. 156</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">PRODUCT NAME: NAMENDA</span></div><div class="nested-key-value"><span class="nested-key">Expiry date: </span><span class="nested-value">20100411</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 5, 2007</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 7, 2006</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 1 AND 10 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 2-9 AND 11-13, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 14-19 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 5, 2004</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20040818</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 29, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 9, 2002</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERZ PHARMA GMBH &amp; CO. KGAA, GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:MERZ PHARMA GMBH &amp; CO. KGAA DOING BUSINESS AS MERZ PHARMACEUTICALS GMBH;REEL/FRAME:013372/0354</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20020827</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 1, 2002</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERZ PHARMA GMBH &amp; CO. KGAA, DBA MERZ PHARMACEUTIC</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:MERZ+CO. GMBH &amp; CO.;REEL/FRAME:012865/0219</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20020416</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:MERZ+CO. GMBH &amp; CO. /AR;REEL/FRAME:012865/0219</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 29, 1999</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 30, 1994</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 7, 1990</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERZ + CO. GBMH &amp; CO., GERMANY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BORMANN, JOACHIM;GOLD, MARKUS R.;SCHATTON, WOLFGANG;REEL/FRAME:005302/0141</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19900321</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2UZ3EuuLgh1O4GKf80fUJgp95mkQ\u0026id=7VwxBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1uGacn5qqsDltBxwgKFBm8NtfBnA\u0026id=7VwxBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U189hYEtsFRZmRJxHid-aT1n_36zQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Alzheimer_s_disease.pdf?id=7VwxBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0F4oG670OdkAHqFezaX65BY_t5_A"},"sample_url":"http://www.google.com/patents/reader?id=7VwxBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>